Neuland Laboratories Limited (NEULANDLAB.BO)
INR 14649.65
(-0.98%)
INR 14649.65
(-0.98%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 953.89 Million INR | -25.74% |
| 2022 | 1.28 Billion INR | -46.6% |
| 2021 | 2.4 Billion INR | 31.95% |
| 2020 | 1.82 Billion INR | -30.88% |
| 2019 | 2.63 Billion INR | 13.94% |
| 2018 | 2.31 Billion INR | -27.49% |
| 2017 | 3.19 Billion INR | 66.16% |
| 2016 | 1.92 Billion INR | 13.13% |
| 2015 | 1.69 Billion INR | -5.14% |
| 2014 | 1.79 Billion INR | 3.19% |
| 2013 | 1.73 Billion INR | -5.61% |
| 2012 | 1.83 Billion INR | -2.21% |
| 2011 | 1.87 Billion INR | -8.57% |
| 2010 | 2.05 Billion INR | -11.85% |
| 2009 | 2.33 Billion INR | 16.41% |
| 2008 | 2 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 953.89 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 953.89 Million INR | -25.74% |
| 2023 Q2 | 1 Billion INR | 0.0% |
| 2022 Q2 | 2.08 Billion INR | 0.0% |
| 2022 FY | 1.28 Billion INR | -46.6% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 1.28 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.27 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 2.4 Billion INR | 31.95% |
| 2021 Q4 | 2.4 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.23 Billion INR | 0.0% |
| 2020 FY | 1.82 Billion INR | -30.88% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 1.82 Billion INR | 0.0% |
| 2019 Q4 | 2.63 Billion INR | 0.0% |
| 2019 FY | 2.63 Billion INR | 13.94% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 2 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 2.31 Billion INR | -27.49% |
| 2018 Q4 | 2.31 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 3.19 Billion INR | 66.16% |
| 2016 Q3 | 2.04 Billion INR | 22.24% |
| 2016 Q1 | - INR | 0.0% |
| 2016 Q2 | 1.67 Billion INR | 0.0% |
| 2016 FY | 1.92 Billion INR | 13.13% |
| 2016 Q4 | 1.92 Billion INR | -5.94% |
| 2015 FY | 1.69 Billion INR | -5.14% |
| 2014 FY | 1.79 Billion INR | 3.19% |
| 2013 FY | 1.73 Billion INR | -5.61% |
| 2012 FY | 1.83 Billion INR | -2.21% |
| 2011 FY | 1.87 Billion INR | -8.57% |
| 2010 FY | 2.05 Billion INR | -11.85% |
| 2009 FY | 2.33 Billion INR | 16.41% |
| 2008 FY | 2 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -170.379% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -5419.273% |
| Sigachi Industries Limited | 1.43 Billion INR | 33.318% |
| Bal Pharma Limited | 1.39 Billion INR | 31.693% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -473.889% |
| Medico Remedies Limited | 80.5 Million INR | -1084.905% |
| Lasa Supergenerics Limited | 220.76 Million INR | -332.092% |
| Venus Remedies Limited | 413.3 Million INR | -130.8% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -55.993% |
| Alpa Laboratories Limited | 52.46 Million INR | -1718.157% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 84.991% |
| Shilpa Medicare Limited | 9.37 Billion INR | 89.824% |
| Aarti Drugs Limited | 5.64 Billion INR | 83.095% |
| Lupin Limited | 29.21 Billion INR | 96.735% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 98.565% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 88.139% |
| Windlas Biotech Limited | 36.41 Million INR | -2519.874% |
| Suven Life Sciences Limited | 7.09 Million INR | -13340.834% |
| Eris Lifesciences Limited | 27.81 Billion INR | 96.57% |
| Valiant Laboratories Limited | 767.08 Million INR | -24.354% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 74.742% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 90.569% |
| Ipca Laboratories Limited | 14.38 Billion INR | 93.368% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 4.458% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 97.086% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 71.339% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 53.956% |
| Laurus Labs Limited | 25.77 Billion INR | 96.299% |
| Piramal Pharma Limited | 47.1 Billion INR | 97.975% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -31.596% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 97.628% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 81.411% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 92.251% |
| Unichem Laboratories Limited | 2.47 Billion INR | 61.461% |
| Sequent Scientific Limited | 4.87 Billion INR | 80.441% |
| Novartis India Limited | 69.7 Million INR | -1268.574% |
| Wanbury Limited | 1.16 Billion INR | 18.11% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -46.761% |
| Wockhardt Limited | 23.56 Billion INR | 95.951% |
| Themis Medicare Limited | 957.92 Million INR | 0.42% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -966.878% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 97.397% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -456.272% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 95.235% |
| Divi's Laboratories Limited | 30 Million INR | -3079.653% |
| NATCO Pharma Limited | 3.71 Billion INR | 74.302% |
| Gufic Biosciences Limited | 3.32 Billion INR | 71.347% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -191.177% |
| Ind-Swift Limited | 10.13 Billion INR | 90.593% |
| Procter & Gamble Health Limited | 95.6 Million INR | -897.799% |
| FDC Limited | 205.18 Million INR | -364.896% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 50.685% |
| Granules India Limited | 13.15 Billion INR | 92.746% |
| Medicamen Biotech Limited | 308.17 Million INR | -209.534% |
| Alkem Laboratories Limited | 14.18 Billion INR | 93.275% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -1974.499% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -21633.789% |
| Brooks Laboratories Limited | 56.41 Million INR | -1590.735% |
| Megasoft Limited | 1.47 Billion INR | 35.13% |
| ZIM Laboratories Limited | 1.08 Billion INR | 12.345% |
| Strides Pharma Science Limited | 25.16 Billion INR | 96.21% |
| Morepen Laboratories Limited | 289.99 Million INR | -228.939% |
| Hikal Limited | 8.17 Billion INR | 88.333% |
| Indoco Remedies Limited | 6.71 Billion INR | 85.804% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 66.559% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -201.422% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 3.15% |
| Hester Biosciences Limited | 2.44 Billion INR | 60.966% |